U.S. Supreme Court: ‘Pay-for-Delay’ Deals Can Be Illegal
On Monday, the U.S. Supreme Court in a 5-3 ruling declared that "pay-for-delay" settlements in the pharmaceutical industry "can sometimes violate" antitrust laws,Â allowing federal regulators to challenge such deals in court. Under pay-for-deal deals, brand-name drugmakers enter into financial agreements with generic drug companies to keep low-cost versions of their products temporarily off the market.
- "Supreme Court Rules 'Pay-for-Delay' Drug Deals Can Be Illegal" (Goad, "RegWatch," The Hill, 6/17).
- "Supreme Court Lets Regulators Sue Over Generic Drug Deals" (Wyatt, New York Times, 6/17).
- "Setback for Pacts That Delay Sale of Generics" (Kendall/Rockoff, Wall Street Journal, 6/17).